- Clinical stage biotech Annovis Bio ( NYSE: ANVS ) traded higher in the morning hours Wednesday after the company highlighted "strong" patient enrollment in its Phase 3 trial for Parkinson's disease (PD) candidate buntanetap.
- "We are very pleased with the pace of enrollment in our Phase 3 study, designed to assess the safety and efficacy of buntanetap in early-stage Parkinson's patients," Chief Executive Maria Maccecchini noted.
- The company has arranged an interim data analysis in Q2 2023 to see if its original target of patients 150 patients per arm will be enough to demonstrate a treatment effect.
- "Based on the current enrollment, the Company anticipates having a sufficient number of patients who have received two months of therapy to conduct an interim analysis in the second quarter of 2023," Annovis ( ANVS ) added.
- Buntanetap, formerly known as ANVS401 or Posiphen, has potential not only in PD but also in Alzheimer's, Seeking Alpha contributor Terry Chrisomalis points out.
For further details see:
Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug